Introduction

Uveitis is a general term describing inflammation of one or all parts of the uveal tract. Deleterious effects on vision, either by acute ocular inflammation or by its sequelae, such as cataracts, glaucoma and retinal vascular ischaemia, make uveitis one of the major causes of visual loss. Uveitis can be broadly classified into those associated with infections and uveitis of a non-infectious aetiology, of which association with systemic autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are well recognised.

Traditionally, corticosteroids are the mainstay treatment in immune-mediated uveitis. Although able to provide prompt and highly effective reduction in inflammation, its wide range of significant side effects precludes long-term usage in high doses. Conventional “steroid-sparing agents” such as antimetabolites, alkylating agents and T-cell inhibitors have proven anti-inflammatory effect associated with improvement in clinical symptoms and quality of life. However, these agents too have potentially serious side effects and patients treated with these medications require careful monitoring for electrolyte imbalances, transaminitis and blood dyscrasias.

Scientific research has identified the key role played by pro-inflammatory chemokines in non-infectious ocular inflammation, such as tumour necrosis factor alpha (TNF-α), interleukins 1, 2 and 6 (IL-1, IL-2, IL-6) and interferon gamma (IFN-γ). It is against these chemokines and their respective receptors that some biologic agents are designed to act, whilst other biologic agents are designed to counteract the secretors of these chemokines, T- and B-cells, thereby aiming to prevent a downward cascade of inflammation. These agents are not only antibodies and antagonists but are also small molecules that inhibit cellular interactions that modulate inflammatory response. As such, biologic agents are also termed “biologic response modifiers”.

Though not fully studied, biologic agents are a new promising option for patients either unresponsive to, or unable to tolerate conventional immunosuppressive therapies, allowing tapering of medication whilst maintaining disease control and in certain cases, remission. This review aims to highlight the current use of biologic agents commonly used in the treatment of uveitis and other ocular inflammatory conditions.

Anti-cytokine Therapy

Anti-tumour Necrosis Factor Alpha

Tumour necrosis factor alpha (TNF-α), an inflammatory...
cytokine produced by macrophages and activated T-cells, plays a key role in neutrophil activation and upregulation of endothelial adhesion molecules. It not only stimulates the proliferation of macrophages, T- and B-cells and T-cell production of pro-inflammatory lymphokines, but is also involved in immunoregulation, host defence, immunosurveillance and cell apoptosis.

The use of anti-TNF agents has revolutionised the treatment of chronic refractory inflammatory disorders. Its efficacy has been proven without doubt in the treatment of systemic diseases such as RA, juvenile idiopathic arthritis (JIA), as well as endogenous, non-infectious refractory uveitis associated with Behcet’s disease and sarcoidosis.

In experimental models, TNF-α has been well demonstrated to play a role in the pathogenesis of uveitis. De Vos et al showed a rise in aqueous humour and serum TNF-α levels in endotoxin-induced uveitis (EIU). Likewise, in experimental autoimmune uveoretinitis (EAU), a CD4 T-helper cell mediated autoimmune response, the roles of anti-TNF-α in suppressing inflammation have also been consistently demonstrated. Of the anti-TNF-α agents available, 3 agents have been described in ocular inflammatory conditions – infliximab, adalimumab and etanercept. Infliximab appears to be most promising and most extensively studied.

**Infliximab**

Infliximab is a chimeric monoclonal antibody that irreversibly and competitively inhibits both membrane bound and circulating TNF-α rapidly. It is to date the most commonly used biologic agent in the treatment of uveitis and its efficacy has been particularly promising, especially in sight-threatening Behcet’s associated uveitis. Successful treatment has also been reported for sarcoidosis, bird-shot chorioretinopathy and multifocal choroiditis (Table 1).

In a prospective trial for the treatment of refractory uveitis, Suhler et al treated 23 patients with infliximab infusions over a period of 50 weeks. Patients received infliximab intravenous (IV) infusions at doses of 3 to 5 mg/kg at weeks 0, 2 and 6 with clinical response being determined at the 10th week. Thereafter, patients received an infusion of infliximab at 8-week intervals.

In this study, the authors reported that 18 out of 23 patients (78.3%) responded to therapy at the 10th week, with reduced inflammation and improvement in visual acuity. Although generally well tolerated, the authors reported an increased rate of serious adverse events including 3 thrombotic events and 1 new onset of congestive cardiac failure.

In a smaller prospective study, Joseph et al reported therapeutic success in the treatment of 5 patients with posterior uveitis unresponsive to the use of other immuno-suppressive agents. Three of their patients had posterior uveitis associated with Behcet’s disease and 2 had posterior segment intraocular inflammation (PSII). Infliximab infusions were given at a dose of 5 mg/kg at weeks 0, 2 and 6.

At 6 weeks, 4 out of 5 patients responded to therapy with remission of posterior uveitis and improvement in visual acuity. Two of these patients relapsed at months 4 and 5 but remission was achieved in the patient with Behcet’s associated uveitis with a repeated dose of infliximab. The other, with idiopathic posterior uveitis, did not respond as well. At 6 months, all 4 patients had successfully withdrawn from other forms of immunosuppressive therapy.

One patient, despite extensive pre-treatment evaluation for tuberculosis, developed pulmonary tuberculosis after receiving infliximab, requiring anti-tuberculostatic medication.

Despite initial success with infliximab, some patients develop a decreasing response to the drug, possibly due to the development of antibodies to the murine portion of the chimeric molecule. Moreover, side effects can be serious and life threatening, warranting close monitoring of its safety and efficacy in its use for treatment of ocular inflammation. Since the approval of treatment of Crohn’s disease and RA with Infliximab by the Food and Drug Administration (FDA) in 1998, there have been rising number of reports of possible lymphomas related to the use of anti-TNF medications. It is imperative that physicians bear the potential development of lymphoproliferative disorders in mind when administering infliximab. With careful monitoring, infliximab is an effective and encouraging treatment option for patients suffering from refractory and sight-threatening uveitis.

**Etanercept**

Etanercept is a dimeric soluble form of the extra cellular ligand-binding protein linked p75 TNF receptor. It has the ability to bind to soluble TNF-α and TNF-β thereby blocking binding to cell surface TNF receptors. However, the complex interaction is unstable and dissociates rapidly which may then only neutralise TNF-α transiently.

Currently approved by the USA FDA for the treatment of RA and psoriatic arthritis, its use in the treatment of uveitis has been evaluated by a number of small studies. Results have not been spectacular; case reports have documented a worsening of anterior uveitis and the development of scleritis in patients, even though the systemic inflammatory disease was brought under control (Table 2).

Reiff et al reported success in the use of etanercept for the treatment of refractory uveitis in children, but other small studies have not reported any apparent benefit of etanercept use in the treatment of both adult and childhood uveitis. Galor et al performed a retrospective analysis on
22 patients treated with anti-TNFα therapy, comparing the effectiveness of etanercept versus infliximab in the treatment of ocular inflammation. They reported a statistically significant difference in the reduction of the inflammation recurrence rate, topical steroid use and treatment response in patients treated with infliximab compared to those treated with etanercept. Whilst there was an initial response in patients treated with etanercept, all eventually required a change in medication to control inflammation.

In summary, whilst proven to be useful in the treatment of systemic RA and juvenile chronic arthritis, etanercept’s efficacy is still controversial for ocular inflammatory disease.

**Adalimumab**

Adalimumab is a fully humanised recombinant anti-TNF-α-specific monoclonal IgG1 antibody. Like infliximab, it has the ability to cause sustained neutralisation of membrane bound TNF-α. Administered subcutaneously, the use of adalimumab in the treatment of systemic RA has been shown to be effective but studies to prove its effectiveness in the treatment of ocular inflammatory disorders are largely lacking.

More recently, Biester et al7 performed a retrospective analysis on 18 patients (children and young adults) treated with adalimumab for refractory juvenile uveitis, both associated with and without arthritis. Twenty to 40 mg injections were given at 2 weekly intervals and increased to a weekly dose if treatment was deemed ineffective.

Of 18 patients, 16 responded to treatment. One had a mild response and 1 did not respond. Therapeutic response was noted within a period of 2 to 16 weeks after commencement of treatment and 15 children were able to come off systemic steroid treatment completely whilst the other 3 children were able to tolerate a lowered dose of corticosteroids.

In this study, side effects of the injection of adalimumab included a mild localised reaction in 1 child, burning sensations and pain surrounding the injection site. There were no anaphylactoid reactions reported and apart from one patient developing herpes simplex keratitis (HSV)-keratitis, no other severe infections were reported.

In summary, adalimumab could be an alternative immunosuppressive drug for the treatment of uveitis. Its use in the treatment of juvenile uveitis and arthritis could help to avoid the side effects of growth retardation and Cushing syndrome associated with corticosteroid use.

**Anti-interleukin Therapies**

Interleukins are a family of cytokines that regulate the growth and function of lymphocytes. Interleukin-1 (IL-1) is produced mainly by macrophages and stimulates

### Table 1. Prospective Studies Ocular Inflammatory Disease Treated With Infliximab

<table>
<thead>
<tr>
<th>Author</th>
<th>n</th>
<th>Types of disease</th>
<th>Response</th>
<th>Dosage</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suhler et al4</td>
<td>23</td>
<td>Idiopathic uveitis, Behçet’s disease, sarcoidosis, bird-shot chorioretinopathy, multifocal choroiditis, Crohn’s disease, pars planitis unrelated to multiple sclerosis</td>
<td>18 out of 23 patients (78.3%) responded to therapy</td>
<td>3 mg/kg infusions if on concurrent immunosuppressants</td>
<td>Myocardial infarction, polyarthritis, new-onset congestive cardiac failure, endometrial carcinoma, non-clearing vitreous haemorrhage, recurrent vitreous haemorrhage, infusion reactions, serum sickness and nephrolithiasis</td>
</tr>
<tr>
<td>Joseph et al5</td>
<td>5</td>
<td>Behçet’s disease, PSII</td>
<td>4 out of 5 (80%) patients responded to therapy at 6 weeks. 2 relapsed remission was achieved with an additional infusion of infliximab</td>
<td>5 mg/kg infusions at 0, 2 and 6 weeks and 8-weekly thereafter</td>
<td>Pulmonary tuberculosis (1 patient)</td>
</tr>
<tr>
<td>Niccoli et al6</td>
<td>12</td>
<td>Behçet’s disease</td>
<td>9 out of 12 patients (75%) achieved complete remission</td>
<td>5 mg/kg over a 12-month period.</td>
<td>Nil serious adverse events reported</td>
</tr>
<tr>
<td>Benitez-del-Castillo et al7</td>
<td>7</td>
<td>Behçet’s disease, sarcoidosis, chronic idiopathic multifocal choroiditis</td>
<td>6 out of 7 patients (85.7%) responded after the first dose. All eyes showed reduced inflammation at 36 months</td>
<td>5 mg/kg infusions at weeks 0, 2 and 6. Repeat infusion administered if patient underwent relapse</td>
<td>Nil ocular or systemic adverse events reported Improvement in subcutaneous granulomas in patient with sarcoidosis</td>
</tr>
</tbody>
</table>

PSII: posterior segment intraocular inflammation
T-helper cells to differentiate and produce other cytokines such as interleukin-2 (IL-2). In turn, IL-2 stimulates both cytotoxic T-cell and T-helper cell growth. Interleukin receptor antagonists specifically prevent T-cell activation and proliferation. With knowledge of the occurrence and properties of naturally occurring interleukin antagonists, such as interleukin 1-RA, biologics designed to mimic the action of such antagonists help provide targeted immunomodulation.18

**Daclizumab**

Daclizumab is a recombinant humanised immunoglobulin G monoclonal antibody that acts as an IL-2 receptor antagonist. IL-2 receptors are expressed on activated T-cell surfaces during inflammation, antagonising the receptor and preventing T-cell proliferation and differentiation.

Well-established to prevent organ rejection in patients receiving renal transplants, the use of daclizumab has also been reported to prevent rejections of cardiac and liver transplants.19-21 In 1999, Nussenblatt et al22 first described successful long-term treatment with daclizumab in patients suffering from severe bilateral uveitis.

In a more recent retrospective study of 14 patients (27 eyes) with ocular inflammatory disorders refractory or intolerant to conventional immunosuppressive agents, Papaliodis et al23 administered intravenous (IV) daclizumab (1 mg/kg) over a period of 1 year. Daclizumab was given
fortnightly for the first 12 weeks, then every 3 weeks for another 12 weeks and finally every 4 weeks until the 52nd week. The diseases included in this study were scleritis, sclerouveitis, ocular-cicatricial pemphigoid (OCP), JIA associated uveitis and idiopathic panuveitis.

Sixteen out of 27 eyes showed improvement in inflammation; 3 out of 27 eyes showed no significant change whilst 8 out of 27 eyes showed worsening in inflammation. No serious adverse reactions were reported. Only 1 patient suffered transient leukopaenia, which required temporary cessation of treatment for 4 weeks until cell counts recovered and treatment was resumed.

Recently, subcutaneous administration of daclizumab has been also been investigated. The study by Nussenblatt and colleagues showed that subcutaneous injections of daclizumab at 2 mg/kg not only allowed greater convenience, but was also well tolerated and allowed concomitant immunosuppressive drug load to be reduced by at least 50% with maintenance of visual acuity.

Daclizumab appears to be relatively well tolerated and may be promising in the treatment of ocular inflammatory disorders that do not respond to conventional methods of treatment.

**Anakinra**

Anakinra is a recombinant human interleukin-1 receptor antagonist (rHuIL1Ra). Preliminary murine studies demonstrated successfully suppression of immune-mediated inflammation with both depressed cellular immune response and cytokine production after the administration of anakinra. It has been reported for use in the treatment of chronic infantile neurological cutaneous articular (CINCA) syndrome. This disease may occur as a result of mutations in the CIAS1 gene, which encodes cryopyrin. Cryopyrin regulates the apoptosis of inflammatory cells; its lack thereof upregulates levels of IL-1. Anakinra competitively inhibits binding of IL-1 and is more effective in the treatment of CINCA syndrome than corticosteroids.

Teoh et al reported successful treatment of posterior uveitis associated with CINCA syndrome in a 4-year-old boy, which had responded poorly to corticosteroids, methotrexate and etanercept. Subcutaneous anakinra was administered at a dose of 1 mg/kg per day until remission was achieved. Inflammatory remission was achieved within the first year of treatment and his uveitis has subsequently remained quiescent, permitting the withdrawal of oral corticosteroids. No adverse side effects were reported.

**Interferon Therapy**

Interferons are cytokines produced in response to viral infections. Synthesised and secreted by monocytes, macrophages, neurons and glial cells, these immunomodulatory substances not only disrupt viral replication, but also prevent tumour growth, act against tolerance inducers of autoimmune disease and have an antiproliferative and apoptotic effect on T-cells. Interferons are classified into type 1 (with alpha and beta subgroups) and type 2 interferons, based on their structure and biologic properties.

**Interferon-α**

As a therapeutic agent, interferon-alpha (IFN-α) has been approved for treatment of hepatitis B and C by limiting viral replication and the Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) showed that patients with an initial clinical episode of demyelination and at least 2 characteristic demyelinating lesions within the brain, treatment with interferon-β1a gave a 50% risk reduction in the development of multiple sclerosis. In inflammatory eye disease,
interferon-α2 (IFN-α2) has mainly been used in the treatment of uveitis associated with Behcet’s disease (Table 3).29,30

A major study by Kotter et al29 in 2003 already reported a response rate of 92% in 50 patients treated for Behcet’s associated uveitis with IFN-α2. More recently, Bodaghi et al30 evaluated 45 patients with sight threatening uveitis resistant to different types of immunosuppressants or requiring high-dose corticosteroids. In this study, the authors, recognising the potential severity of relapsing uveitis, approached the study with all patients receiving corticosteroids with the initiation of IFN-α2. The efficacy of treatment with IFN-α2 was determined by tapering the dosage of corticosteroids until a threshold, beyond which led to a relapse of uveitis, was reached. All other immunomodulating agents were discontinued upon the introduction of IFN-α2. After 4 weeks of treatment, the authors reported that 19 out of 23 patients with Behcet’s associated uveitis responded to IFN-α2 therapy whilst 13 out of 22 patients with uveitis unrelated to Behcet’s disease showed improvement after commencement on IFN-α2.

Major side effects of IFN-α2 therapy were seen in 2 patients. One suffered severe depression, leading to permanent cessation of therapy. The other developed significant neutropenia, requiring temporary interruption in treatment. Minor side effects include flu-like symptoms, coughing, Raynaud’s phenomenon, arthralgias, mild transaminitis and mild/moderate changes in blood cell counts. Patients suffering from these effects did not require discontinuation of IFN-α2 therapy. Common, but rarely symptomatic ophthalmic side effects include retinal lesions such as cotton wool spots, haemorrhages and microaneurysms.

In summary, there is increasing evidence that interferons have a role in the treatment ocular disease, especially in Behcet’s associated uveitis for which, it may be used as second-line therapy for refractory disease. Studies are still required to determine the drug dosage and optimum duration of treatment.

**Anti-Lymphocytic Therapy**

**Anti-B Cell Therapy**

**Rituximab**

Rituximab is a recombinant chimeric monoclonal antibody that targets CD-20, a cell surface antigen on B-cells, resulting in B-cell depletion. Initially developed for the treatment of B-cell lymphomas, its use has recently been applied to the systemic treatment of RA, SLE and Wegener’s granulomatosis (WG). With the established role of B-cells in T-cell mediated and immune complex-mediated diseases, this biologic is potentially useful in targeting the effector cells of the inflammatory cascade.

To date, there have been no randomised control trials (RCT) to show the effectiveness of rituximab for the treatment of ocular inflammation. However, there have been case reports that show therapeutic success in the treatment of scleritis.31,32 It is postulated that since RA, SLE and WG are conditions associated with scleritis, rituximab could emerge as a promising therapeutic agent for ocular inflammation in these situations.

However, there are more reports on the use of rituximab in the treatment of systemic disease. Smith et al33 reported disease control in 11 patients with refractory SLE after commencing treatment on rituximab. Whilst the recurrence rate was high, re-treatment with rituximab was effective and also allowed patients to be maintained on a lower dose of oral corticosteroids. Kramm et al34 treated 5 patients suffering from disease-modifying anti-rheumatic drug (DMARD)-refractory RA with 4 weekly doses of rituximab and achieved remission in 80% after failure of response to anti-TNF therapy.

There have been recent reports of hepatic failure in patients who were hepatitis B carriers, bowel obstruction and perforation, and progressive multifocal leukoencephalopathy (PML) suspected to be associated with the use of rituximab.35,37 Whilst causative effect has not been directly established, it is suggested that its immunosuppressant effects may be associated with PML.

**Other Biologic Agents**

There are other biologic agents being used for the treatment of lymphocytic malignancies and rheumatic disease, such as Campath-1H (alemtuzumab) and newer agents including anti-interleukin-6 antibodies (anti-IL6), and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) therapy. The use of these agents in the treatment of ocular inflammatory conditions is still being explored.

**Campath-1H (Alemtuzumab)**

Campath-1H is a humanised monoclonal antibody that acts against the pan-lymphocyte antigen CD52. Currently approved for use in the treatment of chronic lymphocytic leukaemia, campath-1H is also being investigated for the treatment of T-cell mediated disease such as multiple sclerosis and transplant rejection phenomena.38,39 In 1995, Isaacs et al40 reported its use in the treatment of 1 patient with refractory non-infectious uveitis, with resultant improvement in visual acuity and inflammation. In 2000, Dick et al41 described the treatment of 10 patients with severe refractory non-infectious uveitis, intraocular and orbital inflammatory disease and recurrent corneal allograft rejection with campath-1H. Campath-1H was given by intravenous infusion at 10 to 12 mg daily for 5 days and all
patients demonstrated good clinical response. However, the administration of campath-1H was associated with considerable haemotoxicity and there was a demonstrated universal decrease in total peripheral blood lymphocyte numbers during treatment and a protracted decrease in CD4 counts. As such, campath-1H is less widely used now for the treatment of ocular inflammation as more targeted therapies are available.

**Immunoglobulins**

Intravenous immunoglobulins are purified immunoglobulin G (IgG) products made from pooled human plasma. As an immunomodulating agent, its therapeutic effect has been reported in the treatment of systemic immune-mediated disease such as Guillain-Barre syndrome and Kawasaki disease, prompting evaluation of its application to the treatment of uveitis. In 1999, Rosenbaum et al. reported sustained and substantial benefit for 5 out 10 patients treated with intravenous immunoglobulins for refractory uveitis. Reported side effects included thrombophlebitis, allergic reactions and most significantly, myocardial infarction. Karmochkine et al. also reported successful tapering of corticosteroid dose with improved visual acuity and inflammation in patients treated with intravenous immunoglobulins for birdshot chorioretinopathy. Most recently, Seider et al. described successful treatment of 4 patients suffering from resistant ocular Behcet’s disease with intravenous immunoglobulins. No adverse reactions were reported in this study.

Immunoglobulin therapy is advantageous in that it does not cause immunosuppression and expose the patient to risk of opportunistic infections. However, it is of limited availability, expensive and together with its reported side effects, is not used widely for the treatment of intraocular inflammation.

**Anti-interleukin-6 Therapy**

Still in an experimental stage, scientists have been investigating the possible strategy of targeting interleukin-6 (IL-6) in the treatment of uveitis. Ohta et al. demonstrated in their study, an upregulation of this pro-inflammatory cytokine within aqueous humour in mice with EIU. They also demonstrated a suppression in T-cell activation when the mice were administered anti-IL-6 antibodies, implying potential for targeting treatment against IL-6 for the treatment of uveitis.

**Anti-cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4) Therapy**

T-cell co-stimulating molecules are cell surface proteins that play a role in T-cell activation. CTLA-4 is a T-cell surface receptor that has a high affinity for the B7 surface antigen on B-cells and this receptor-ligand interaction is essential for the induction of T-cells to proliferate and release cytokines.

CTLA-4Fc is a recombinant fusion protein that blocks the interaction between the B-cell surface molecule, B7, and CTLA4 therefore preventing the activation of T-cells and subsequent pro-inflammatory action. Anti-CTLA-4 antibodies have not been reported for use in the treatment of uveitis but have been applied to the treatment of patients with metastatic melanoma with objective tumour responses.

In animal models of EAU, Verwaerde et al. showed that the rodents given intravitreal injections of retinal Müller glial cells transfected with adenovirus expressing CTLA-4-Ig had a strongly protective effects against EAU. Also using the same animal model, Shao et al. demonstrated the expression of B7 in the eye at different times during EAU and the inhibition of EAU in rats treated with anti-B7 antibodies. There is also a suggestion that CTLA-4 may represent a candidate gene for disease susceptibility in Fuchs heterochromic cyclitis. Such evidence suggests an attractive alternative in inhibiting antigen presentation for the treatment of immune-mediated disease and further research is necessary to evaluate the role of CTLA-4 antibodies in the treatment of ocular inflammatory disease.

**Conclusion**

Refractory uveitis along with other treatment-resistant ocular inflammatory disorders can be difficult to treat. Very often, treatment requires prolonged immunosuppression and treatment with corticosteroids and steroid sparing agents have considerable side effects with long-term use.

Studies into the potential use of biologic agents provide ophthalmologists with exciting prospects in successful treatment of such recalcitrant diseases. Infliximab is the most commonly used biologic agent with greatest experience. Moreover, there now exists a larger array of biologic agents that ophthalmologists and physicians can select from, to provide more targeted treatment tailored to the primary driving cytokine response or inflammatory drive. However, there remains a need for larger long-term randomised controlled studies aimed at investigating the use of these agents, to address the dose, duration efficacy and long-term complications resulting from prolonged biologic agent administration in patients with uveitis.

Treatment benefit must also be balanced against the potential financial implications for both patients and respective health systems. In our local setting, biologics are expensive. On average, infliximab currently costs approximately $3000 per dose, rituximab and etanercept approximately $3000 to $4000 per month of treatment.
whilst IFN-α2 costs approximately $1200 per month of treatment. Furthermore, biologic agents are not currently subsidised or funded by health insurance, which implicates further financial burden on the patient. With escalating healthcare costs and potential side effects, most importantly those of malignancies, these drugs therefore need to be used judiciously, with the patient being well informed of implications, risks and benefits of therapy.

REFERENCES


